Reata announces improvements in kidney function with bardoxolone methyl
Reata Pharma announced results from the long-term follow up portion of the LARIAT study demonstrating that PAH patients treated with bardoxolone methyl (bardoxolone) experienced kidney function improvements that were durable for two years and not associated with adverse outcomes. February 12, 2018